Amyloidosis - 257 Studies Found
Active, not recruiting |
: Safety And Efficacy Evaluation Of Fx-1006A In Subjects With Transthyretin Amyloidosis : ATTR-PN : 2009-06-17 : Drug: Tafamidis 20 mg oral Fx-1006A daily |
Not yet recruiting |
: Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease : Cardiac TTR Amyloidosis : 2017-03-28 : Diagnostic Test: Tc99m-labeled pyrophosphate scan Intravenous injection of Tc99m-labeled pyrophosphate w |
Withdrawn |
: The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart : Amyloidosis : 2015-11-19 : Drug: Isis 420915/GSK 299872 Open label study in comparison to historic control. |
Active, not recruiting |
: Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy :
: 2013-03-12 : Drug: Tauroursodeoxycholic Acid and Doxycycline |
Recruiting |
: A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis : Amyloidosis : 2015-11-09 : Drug: GSK3039294 GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple cap |
Completed |
: A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis : Amyloidosis : 2013-01-24 :
|
Recruiting |
: Body Composition in Systemic Amyloidosis : Amyloidosis : 2014-02-24 : Other: Dietary advice Standard dietary advice are provided to all patients at baseline and during the fo |
Not yet recruiting |
: Renal AL Amyloid Involvement and NEOD001 : Amyloidosis : 2017-04-26 :
|
Recruiting |
: Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography : Cardiac Amyloidosis : 2012-09-04 : Drug: F-18 florbetapir PET Cardiac PET images will be obtained following injection of F-18 labeled Florb |
Completed |
: Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis : Amyloidosis : 2015-06-24 : Drug: bortezominb and dexamethasone The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexa |